{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:38:54Z","timestamp":1789839534967,"version":"4.0.1"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA177558"],"award-info":[{"award-number":["P30 CA177558"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Artesunate is the most common treatment for malaria throughout the world. Artesunate has anticancer activity likely through the induction of reactive oxygen species, the same mechanism of action utilized in Plasmodium falciparum infections. Components of the kelch-like ECH-associated protein 1 (KEAP1)\/nuclear factor erythroid 2-related factor 2 (NRF2) pathway, which regulates cellular response to oxidative stress, are mutated in approximately 30% of non-small-cell lung cancers (NSCLC); therefore, we tested the hypothesis that KEAP1 is required for artesunate sensitivity in NSCLC. Dose response assays identified A549 cells, which have a G333C-inactivating mutation in KEAP1, as resistant to artesunate, with an IC50 of 23.6 \u00b5M, while H1299 and H1563 cells were sensitive to artesunate, with a 10-fold lower IC50. Knockdown of KEAP1 through siRNA caused increased resistance to artesunate in H1299 cells. Alternatively, the pharmacological inhibition of NRF2, which is activated downstream of KEAP1 loss, by ML385 partially restored sensitivity of A549 cells to artesunate, and the combination of artesunate and ML385 was synergistic in both A549 and H1299 cells. These findings demonstrate that KEAP1 is required for the anticancer activity of artesunate and support the further development of NRF2 inhibitors to target patients with mutations in the KEAP1\/NRF2 pathway.<\/jats:p>","DOI":"10.3390\/cancers13081885","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:35:12Z","timestamp":1618443312000},"page":"1885","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3757-2822","authenticated-orcid":false,"given":"Kristen S.","family":"Hill","sequence":"first","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"McDowell","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, College of Medicine, University of Kentucky, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Robert","family":"McCorkle","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Schuler","sequence":"additional","affiliation":[{"name":"Department of Pathology, College of Medicine, University of Kentucky, Lexington, KY 40508, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally R.","family":"Ellingson","sequence":"additional","affiliation":[{"name":"Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY 40506, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Plattner","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40508, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1802-6439","authenticated-orcid":false,"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington, KY 40536, USA"},{"name":"Department of Pharmacy Practice and Research, College of Pharmacy, University of Kentucky, Lexington, KY 40508, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"ref_1","unstructured":"Chemical studies on qinghaosu (artemisinine) (1982). China Cooperative Research Group on qinghaosu and its derivatives as antimalarials. J. Tradit. Chin. Med., 2, 3\u20138."},{"key":"ref_2","unstructured":"(2015). Guidelines for the Treatment of Malaria, WHO. [3rd ed.]. WHO Guidelines Approved by the Guidelines Review Committee."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s11427-015-4948-7","article-title":"The discovery of artemisinin and the Nobel Prize in Physiology or Medicine","volume":"58","author":"Su","year":"2015","journal-title":"Sci. China Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1248\/bpb.b17-00855","article-title":"Mechanisms of the pH- and Oxygen-Dependent Oxidation Activities of Artesunate","volume":"41","author":"Tsuda","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3736\/jcim20080206","article-title":"Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial","volume":"6","author":"Zhang","year":"2008","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature12876","article-title":"A molecular marker of artemisinin-resistant Plasmodium falciparum malaria","volume":"505","author":"Ariey","year":"2014","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/infdis\/jiy649","article-title":"Optimal Treatments for Severe Malaria and the Threat Posed by Artemisinin Resistance","volume":"219","author":"Jones","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.pt.2016.05.010","article-title":"Artemisinin Action and Resistance in Plasmodium falciparum","volume":"32","author":"Tilley","year":"2016","journal-title":"Trends Parasitol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12964-020-00568-z","article-title":"Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1\/NRF2 pathway activation","volume":"18","author":"Gong","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/0008-5472.CAN-13-1655","article-title":"Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination","volume":"74","author":"Hast","year":"2014","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., Herman, J.G., Baylin, S.B., Sidransky, D., and Gabrielson, E. (2006). Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030420"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"key":"ref_13","first-page":"887","article-title":"NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes","volume":"27","author":"Singh","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jtho.2019.07.003","article-title":"Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma","volume":"14","author":"Goeman","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2019.05.002","article-title":"Impact of KEAP1\/NFE2L2\/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer","volume":"134","author":"Hellyer","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ebiom.2019.06.022","article-title":"FAM129B, an antioxidative protein, reduces chemosensitivity by competing with Nrf2 for Keap1 binding","volume":"45","author":"Cheng","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.cell.2019.06.003","article-title":"Nrf2 Activation Promotes Lung Cancer Metastasis by Inhibiting the Degradation of Bach1","volume":"178","author":"Lignitto","year":"2019","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Srinivas, U.S., Tan, B.W.Q., Vellayappan, B.A., and Jeyasekharan, A.D. (2019). ROS and the DNA damage response in cancer. Redox Biol., 25.","DOI":"10.1016\/j.redox.2018.101084"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcdb.2017.05.023","article-title":"ROS signalling in the biology of cancer","volume":"80","author":"Moloney","year":"2018","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1021\/acschembio.6b00651","article-title":"Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors","volume":"11","author":"Singh","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1101\/gad.225680.113","article-title":"The emerging role of the Nrf2-Keap1 signaling pathway in cancer","volume":"27","author":"Jaramillo","year":"2013","journal-title":"Gen. Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The Toxicity of Poisons Applied Jointly1","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","article-title":"Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases","volume":"18","author":"Cuadrado","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.clinthera.2017.06.012","article-title":"Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM","volume":"39","author":"Fernandez","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1940-6207.CAPR-11-0538","article-title":"Protection of humans by plant glucosinolates: Efficiency of conversion of glucosinolates to isothiocyanates by the gastrointestinal microflora","volume":"5","author":"Fahey","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Byakika-Kibwika, P., Lamorde, M., Mayito, J., Nabukeera, L., Mayanja-Kizza, H., Katabira, E., Hanpithakpong, W., Obua, C., Pakker, N., and Lindegardh, N. (2012). Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults. Malar. J., 11.","DOI":"10.1186\/1475-2875-11-132"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00280-018-3533-8","article-title":"A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies","volume":"81","author":"Deeken","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1158\/1535-7163.MCT-11-0534","article-title":"Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM\/ATR damage response in cancer cells","volume":"10","author":"Berdelle","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/fcp.12266","article-title":"Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt\/mTOR and inducing oxidative stress","volume":"31","author":"Li","year":"2017","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4939-7493-1_17","article-title":"Methods for High-throughput Drug Combination Screening and Synergy Scoring","volume":"1711","author":"He","year":"2018","journal-title":"Methods Mol. Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1885\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:48:06Z","timestamp":1760161686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13081885"],"URL":"https:\/\/doi.org\/10.3390\/cancers13081885","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]}}}